JP2023506452A5 - - Google Patents
Info
- Publication number
- JP2023506452A5 JP2023506452A5 JP2022535518A JP2022535518A JP2023506452A5 JP 2023506452 A5 JP2023506452 A5 JP 2023506452A5 JP 2022535518 A JP2022535518 A JP 2022535518A JP 2022535518 A JP2022535518 A JP 2022535518A JP 2023506452 A5 JP2023506452 A5 JP 2023506452A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antibody
- seq
- fusion protein
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962947686P | 2019-12-13 | 2019-12-13 | |
| US62/947,686 | 2019-12-13 | ||
| PCT/US2020/064515 WO2021119429A1 (en) | 2019-12-13 | 2020-12-11 | Novel interleukin-15 (il-15) fusion proteins and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023506452A JP2023506452A (ja) | 2023-02-16 |
| JP2023506452A5 true JP2023506452A5 (https=) | 2023-12-19 |
| JP7807076B2 JP7807076B2 (ja) | 2026-01-27 |
Family
ID=76330576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535518A Active JP7807076B2 (ja) | 2019-12-13 | 2020-12-11 | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230048046A1 (https=) |
| EP (2) | EP4072588A4 (https=) |
| JP (1) | JP7807076B2 (https=) |
| KR (1) | KR20220114063A (https=) |
| CN (1) | CN115087464B (https=) |
| AU (1) | AU2020402097A1 (https=) |
| CA (1) | CA3164337A1 (https=) |
| WO (1) | WO2021119429A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| WO2019204646A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
| MA52289A (fr) | 2018-04-18 | 2021-02-24 | Xencor Inc | Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations |
| US20220002370A1 (en) | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
| CN111423510B (zh) * | 2019-01-10 | 2024-02-06 | 迈威(上海)生物科技股份有限公司 | 重组抗人pd-1抗体及其应用 |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| WO2022012428A1 (zh) * | 2020-07-14 | 2022-01-20 | 迈威(上海)生物科技股份有限公司 | 抗pd-1抗体及其稳定制剂 |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| JP2024527593A (ja) * | 2021-07-09 | 2024-07-25 | レジェンド バイオテック アイルランド リミテッド | 変異型ｉｌ－１５組成物及びその方法 |
| WO2023048518A1 (ko) * | 2021-09-24 | 2023-03-30 | 바이오엔시스템스 주식회사 | Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도 |
| WO2023133424A2 (en) * | 2022-01-05 | 2023-07-13 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides |
| JP2025507733A (ja) * | 2022-02-28 | 2025-03-21 | ウーシー バイオロジクス アイルランド リミテッド | Ｉｌ－１５変異体を含むヘテロ二量体ポリペプチド錯体とその使用 |
| WO2023196905A1 (en) * | 2022-04-07 | 2023-10-12 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
| CN116854821A (zh) * | 2022-08-15 | 2023-10-10 | 海徕科(北京)生物技术有限公司 | IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途 |
| CN116063512B (zh) * | 2022-10-13 | 2025-11-07 | 深圳市百士通科技开发有限公司 | 多功能重组抗体及其制备方法和应用 |
| KR20250135294A (ko) * | 2023-02-21 | 2025-09-12 | 레메젠 코, 리미티드 | 암을 위한 il-15 작용제 |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| WO2025252855A1 (en) * | 2024-06-05 | 2025-12-11 | Institut National de la Santé et de la Recherche Médicale | IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta |
| CN118995825B (zh) * | 2024-10-24 | 2025-02-07 | 星奕昂(上海)生物科技有限公司 | 一种特异性定量标定白细胞介素15活性的细胞系及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| CN1703423A (zh) * | 2002-10-14 | 2005-11-30 | 豪夫迈－罗氏公司 | Il－15拮抗剂 |
| CA2509365C (en) | 2002-12-09 | 2012-08-07 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| CL2008003526A1 (es) | 2007-11-30 | 2010-01-11 | Medarex Inc | Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer. |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| NO2344540T3 (https=) * | 2008-10-02 | 2018-04-28 | ||
| BR112012007875A2 (pt) | 2009-07-31 | 2016-11-22 | Medarex Inc | anticorpos totalmente humanos para btla |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| AU2011262758B8 (en) | 2010-06-11 | 2014-09-04 | Kyowa Kirin Co., Ltd. | Anti-tim-3 antibody |
| US20150359853A1 (en) * | 2012-10-24 | 2015-12-17 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| RU2689717C2 (ru) * | 2014-01-08 | 2019-05-28 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Гетеродимерный белок il-15 и его применения |
| WO2017046200A1 (en) * | 2015-09-16 | 2017-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
| TW201741337A (zh) * | 2016-05-13 | 2017-12-01 | 麥迪紐有限責任公司 | ＣＤ４０Ｌ-Ｆｃ融合多肽及其使用方法 |
| MY203000A (en) | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
| WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| CA3086040A1 (en) * | 2017-12-19 | 2019-06-27 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
| CN112004547A (zh) * | 2018-02-26 | 2020-11-27 | 新索思股份有限公司 | Il-15缀合物及其用途 |
| CA3090407A1 (en) | 2018-03-01 | 2019-09-06 | Glycotope Gmbh | Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
| MA52289A (fr) * | 2018-04-18 | 2021-02-24 | Xencor Inc | Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations |
| EP3810171B1 (en) * | 2018-06-22 | 2025-07-09 | Cugene Inc. | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
| AU2019359475A1 (en) * | 2018-10-12 | 2021-05-20 | Xencor, Inc. | PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof |
| MX2022007202A (es) * | 2019-12-13 | 2022-10-07 | Cugene Inc | Fármacos bioactivables a base de citocinas y metodos de uso de los mismos. |
-
2020
- 2020-12-11 JP JP2022535518A patent/JP7807076B2/ja active Active
- 2020-12-11 KR KR1020227024241A patent/KR20220114063A/ko active Pending
- 2020-12-11 US US17/784,186 patent/US20230048046A1/en active Pending
- 2020-12-11 EP EP20899197.6A patent/EP4072588A4/en not_active Withdrawn
- 2020-12-11 WO PCT/US2020/064515 patent/WO2021119429A1/en not_active Ceased
- 2020-12-11 CA CA3164337A patent/CA3164337A1/en active Pending
- 2020-12-11 AU AU2020402097A patent/AU2020402097A1/en active Pending
- 2020-12-11 EP EP24191000.9A patent/EP4461750A3/en active Pending
- 2020-12-11 CN CN202080096546.5A patent/CN115087464B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023506452A5 (https=) | ||
| JP2022536345A5 (https=) | ||
| JP6618463B2 (ja) | 三量体型抗原結合分子 | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| JP2025065142A5 (https=) | ||
| JP2022105574A (ja) | 多重特異性分子 | |
| JP2022513116A5 (https=) | ||
| EP3253795B1 (en) | Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments | |
| JP2019524693A5 (https=) | ||
| JP2019528077A5 (https=) | ||
| JP2022536347A5 (https=) | ||
| JP2021515806A (ja) | 三重特異性抗原結合タンパク質 | |
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| RU2017129591A (ru) | МАт-НАПРАВЛЯЕМЫЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРНЫЕ СИСТЕМЫ ДЛЯ СОРТИРОВКИ/ИСТОЩЕНИЯ СКОНСТРУИРОВАННЫХ ИММУННЫХ КЛЕТОК | |
| JP2024023228A5 (https=) | ||
| JP2019531704A5 (https=) | ||
| RU2015129640A (ru) | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 | |
| JP2017521998A (ja) | 新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法 | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2024509910A5 (https=) | ||
| CN115605513A (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
| JP2022548112A5 (https=) | ||
| JP2024527020A5 (https=) | ||
| CN120548192A (zh) | 免疫缀合物 |